Rocket Lab's Dual Dilemma: Pentagon Wins Can't Outweigh Iridium Uncertainty

Rocket Lab shares fell 11% weekly amid SpaceX FCC complaint over Iridium deal; defense contracts and Neutron delays shape outlook.

There's an uncomfortable arithmetic at work in Rocket Lab's share price right now, and it has little to do with how many satellites the company can build. The stock closed Friday at €55.60, down 4.1 percent on the day and roughly 11 percent lower on the week — a slide that reflects a growing disconnect between the company's operational momentum and the regulatory fog enveloping its biggest acquisition yet.

The most immediate overhang comes from a formal complaint SpaceX filed with the FCC regarding Iridium Communications' conduct. That filing matters enormously to Rocket Lab because its roughly $8.0 billion takeover of Iridium is tied to a variable exchange ratio based on Rocket Lab's own share price. Every euro the stock falls effectively worsens the deal's terms for Rocket Lab shareholders, translating regulatory friction directly into market pressure.

A Pipeline That Keeps Growing

Yet even as the stock struggles, the contract wins keep stacking up. The Space Systems Command of the US Space Force awarded Rocket Lab $90 million to build and operate two geostationary satellites carrying the "Heimdall" space-domain awareness payload — the company's first operational program in that orbital segment, and a strategic foothold that extends well beyond the dollar value of the contract itself.

That followed a $397 million award for so-called "Flatellites," satellites designed to track airborne threats in real time as part of the Pentagon's "Golden Dome" missile-defense initiative. The deal reinforces the narrative of a company transforming from a niche launch provider into a defense and space-infrastructure contractor — the core growth story investors are betting on.

The momentum continued on August 17, when the Space Force added Rocket Lab to the NITE-STAR indefinite delivery/indefinite quantity contract, a vehicle with a program ceiling of up to $981 million. A day later came two initial task orders worth a combined $12 million under the Space Data Network Consortium, with a Photon spacecraft slated to demonstrate optical communications in orbit.

Neutron Slips, Insiders Sell

The operational picture isn't entirely rosy, however. Media reports suggest the maiden flight of the medium-lift Neutron rocket could slip into 2027, after the company had previously targeted late 2026. The culprit appears to be issues with main propellant tank testing. For a company whose valuation is partly built on the Neutron story, that's not a footnote. Rocket Lab, for its part, stresses that launch readiness matters more than a target date — a familiar refrain in an industry where delays are the norm rather than the exception.

Meanwhile, a cluster of insider transactions has added to the nervousness. COO Frank Klein sold shares on August 24 and again on August 27, totaling roughly $5.5 million. CFO Adam Spice sold to cover tax obligations, and SVP Arjun Kampani offloaded a smaller position. All three transactions ran through pre-arranged Rule 10b5-1 plans — legally unremarkable, but the optics are poor when the stock is already under pressure.

The technical picture reinforces the corrective mood. At €55.60, the shares sit 58 percent below their 52-week high of €133.80 and well under the 200-day moving average of €69.32. The RSI of 34.8 points to oversold conditions, and the stock's 18 percent discount to its 50-day average shows how badly the recent slide has damaged the short-term trend.

A Stock Caught Between Two Stories

Still, context matters. The shares remain 71 percent above the 52-week low of €32.60, and they're up 35 percent over the past twelve months — evidence of a structural re-rating since the Golden Dome narrative gained traction. On August 19, analysts lifted their consensus price target to $114.33 from $103.91, citing higher revenue expectations from the planned Iridium acquisition, though with a lower margin forecast. That estimate predates the SpaceX complaint and doesn't yet reflect the current regulatory picture.

The insider selling deserves similar perspective. Frank Klein, after his sales, still holds 925,737 shares worth over $62 million — hardly the posture of someone heading for the exit. These are programmed diversification moves by executives whose wealth is disproportionately tied to a single, highly volatile stock.

What makes Rocket Lab emblematic of the broader "New Space" trade is precisely this duality: operational progress that keeps getting overshadowed by political and regulatory risk, with the valuation swinging between future promise and present uncertainty. The market increasingly treats space stocks as their own asset class — on a single day, SpaceX, Intuitive Machines, and Rocket Lab all jumped 8 to 11 percent on collective sector enthusiasm — which means the group rises and falls together, for better and worse.

For now, Rocket Lab is a defense contractor with space-stock volatility, and that dual identity will keep driving the share price in the months ahead. The question investors are wrestling with isn't whether the company can win contracts — it's whether the Iridium deal's mechanics, the Neutron timeline, and the regulatory noise will keep the stock hostage to forces beyond its control.